Posted by Michael Wonder on 26 Apr 2021
LEO Pharma receives positive CHMP opinion of Adtralza (tralokinumab) for the treatment of adults with moderate-to-severe atopic dermatitis
23 April 2021 - The CHMP opinion is primarily supported by data from ECZTRA 1, 2, and 3 trials included in the marketing authorisation application.
LEO Pharma today announced that the CHMP of the EMA has adopted a positive opinion and recommended granting a marketing authorization of Adtralza (tralokinumab) for the treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy.
